Dizal (jiangsu) Pharmaceutical Co., Ltd.

Other

Merck Sharp + Dohme Corp.

Dizal Pharmaceutical Co., Limited

Honchung Tsui

Xiaolin Zhang

Zhenfan Yang

Qingbei Zeng

Changhe Qi

Zhengtao Li

Wei Zhu

Jiabing Wang

Xiang Chen

Hao Zou

Changmao Shen

Wei Zhong

Rumin Wang

Wengeng Liu

Michael D Altman

Jongwon Lim

Craig R Gibeau

Matthew Lloyd Childers

Ginny Dai Ho

The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

Triazolo-pyrimidine compounds and uses thereof

The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.

Pyrazine compounds and uses thereof

Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

ErbB/BTK inhibitors

Disclosed are quinazoline compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds which are useful in treating diseases associated ErbBs. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

ERBB receptor inhibitors

Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

ErbB receptor inhibitors

The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases. 

Carboxamide inhibitors of IRAK4 activity

Growing community of inventors

Shanghai, China

Honchung Tsui